Tags : Hereditary Transthyretin-Mediated Amyloidosis

Ionis’ Tegsedi (inotersen) Receives FDA Approval for Polyneuropathy of Hereditary

Vartika Singh October 5, 2018

Shots: The approval is based on P-III NEURO-TTR study trial assessing Tegsedi vs PBO in 172 patients in ratio (2:1) with hATTR amyloidosis with symptoms of polyneuropathy The study resulted […]readmore

Tags : Hereditary Transthyretin-Mediated Amyloidosis

Ionis’ Tegsedi (inotersen) Receives FDA Approval for Polyneuropathy of Hereditary

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : Hereditary Transthyretin-Mediated Amyloidosis

﻿Ionis’ Tegsedi (inotersen) Receives FDA Approval for Polyneuropathy of Hereditary

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company

Ionis’ Tegsedi (inotersen) Receives FDA Approval for Polyneuropathy of Hereditary